The Editors Of The Lancet Onco. Expression of concern-Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol 2023 Dec 21:S1470-2045(23)00673.
PMID: 38142701